Matthew Johnson: Psychedelics | Lex Fridman Podcast #145

Compounds like psilocybin and LSD act mainly as serotonin 2A agonists, can be taken at very high multiples of an effective dose without organ toxicity or lethal overdose in screened individuals, but can induce the most intense psychological experiences of a person’s life.

While substances like cocaine, alcohol, and nicotine readily produce daily-use patterns and dependence, people almost never compulsively use psychedelics; repeated daily use is usually about dares or tolerance, not loss of control.

Under high-dose intoxication, people can do reckless things (e.g., walking into traffic, falling from heights), so controlled settings with trained guides and safe environments are essential for minimizing harm.

In Johnson’s pilot study, ~80% of long-term smokers were biologically confirmed abstinent at 6 months and ~60% at 2.5 years after psilocybin-assisted therapy—rates at least comparable to or exceeding best-in-class conventional methods, prompting larger randomized trials.

High-dose sessions often lead people to say they didn’t know such experiences were possible; the drugs seem to reduce the grip of ingrained assumptions and heuristics, temporarily increasing mental flexibility and openness to new perspectives.

Johnson uses concepts like demand curves, price elasticity, and delayed discounting to show how addicts overvalue immediate rewards (e.g., smoking now) and undervalue future consequences (e.g., cancer later), modeling the internal conflict between “short-term” and “long-term” selves.

Psilocybin sessions at Hopkins include extensive preparatory therapy, safe ‘living-room’ settings, eye shades, music, and support from guides; participants are encouraged to surrender to the experience, approach inner “monsters,” and fully feel difficult emotions rather than resist them.